Published in Medical Letter on the CDC and FDA, July 30th, 2006
The guidance provides greater transparency by explaining how the agency will conduct its early safety evaluation of new proteins in new plant varieties, including bioengineered varieties, that are in development for possible use as food for humans or animals. This guidance is focused on resolving any potential food safety issues prior to possible inadvertent introduction of material from a new plant variety for which FDA has not been consulted.
FDA has not found, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.